The £1.61m ($2m) grant from Innovate UK was secured by Oxford genetics in order to undertake a research project exploring computational and synthetic biology approaches for optimising mammalian biomanufacturing processes.
“The production yields of many biological drugs are often very low, or at least unpredictable or variable,” CEO Ryan Cawood told Biopharma-Reporter.com. “For this reason by using statistical analysis to try and remove any uncertainty by designing proteins, viruses and cells better we can reduce these challenges.”
The funding will be spent primarily on internal research over a three year period, done in collaboration with the University of Oxford.
“The grant aims to deliver services to our biopharmaceutical clients by providing improved bioinformatics and software, coupled with a range of in house tools that we can help to deliver consistency and high productivity in the services we provide,” Cawood said.
The news comes a month after Oxford Genetics secured a $1m grant – also from Innovate UK – to conduct research into increasing the efficiency and reducing the cost of scaling-up viral vector production.